Drug

Insulin detemir

Approved medicine

ClassInsulin receptor agonistResearchOngoing clinical research

Also known as Detemir, Levemir, Insulina detemir, Insulin Detemir (Recombinant)+1 more

Detemir, Levemir, Insulina detemir, Insulin Detemir (Recombinant), Insulin detemir recombinant.

RxNorm139825 ChEMBLCHEMBL2104391 ATCA10AE05UNII4FT78T86XV

Research papers

Active clinical trials

Insulin receptor

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Study Investigating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes

Clinical trial2026-03-18Completed · ClinicalTrials.gov

Making an "Obese"Brain(and Body)Lean: Insulin Detemir,Monoamines,and Reward

Clinical trial2026-01-23Results expected Q4 2028 · ClinicalTrials.gov

A Phase 2 Open Label Randomized Controlled Trial Determir Vs Neutral Protamine Hagedorn (NPH) In Pregnant Women: DETERMINE Study

Clinical trial2025-06-01Primary completion · ClinicalTrials.gov

Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment

Clinical trial2024-02-21Terminated · ClinicalTrials.gov

A 20-week, Multi-centre, Open-labelled, Non-comparative Evaluation of the Safety and Efficacy of Insulin Detemir in Combination With Oral Anti-diabetic Drug(s), in Subjects With Type 2 Diabetes Mellitus Who Were Inadequately Controlled on Current Therapy in Korea

Clinical trial2024-02-01Results posted · ClinicalTrials.gov

A 12-months Multi-national, Multi-centre, Double Blind, Randomised, Parallel Safety and Efficacy Comparison of Insulin Detemir Produced by the Current Process and Insulin Detemir Produced by the NN729 Process in Subjects With Type 1 Diabetes on a Basal-bolus Regimen With Insulin Aspart as the Bolus Insulin

Clinical trial2024-01-02Results posted · ClinicalTrials.gov

A Trial Comparing the Effect and Safety of Insulin Degludec Versus Insulin Detemir, Both in Combination With Insulin Aspart, in the Treatment of Pregnant Women With Type 1 Diabetes

Clinical trial2023-01-20Results posted · ClinicalTrials.gov

A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes

Clinical trial2022-05-06Completed · ClinicalTrials.gov

Management of Hyperglycemia in the Emergency Room: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care

Clinical trial2022-02-07Results posted · ClinicalTrials.gov

Effectiveness of a Subcutaneously Administered Long-Acting Insulin Detemir Added to Insulin Drip Therapy as Compared With Standard Insulin Drip Treatment

Clinical trial2021-12-07Results posted · ClinicalTrials.gov

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

Clinical trial2020-11-17Results posted · ClinicalTrials.gov

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.

Research2009-06-01Diabetes, obesity & metabolism

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Insulin detemir

Aliases & brands

DetemirLevemirInsulina detemirInsulin Detemir (Recombinant)Insulin detemir recombinant

RxNorm CUI

139825

ChEMBL ID

CHEMBL2104391

ATC codes

A10AE05

UNII

4FT78T86XV

Primary mechanism

Insulin receptor agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Insulin receptor

INSR · P06213

AGONISTInsulin receptor agonist

Clinical trials

113 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

113

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 113

Phase 117Phase 24Phase 2 / 31Phase 342Phase 437Phase N / A12

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in Insulin-naive Patients With Uncontrolled Type 2 Diabetes Mellitus

CompletedPH IVKey trialSanofin=3,3042018

The Effect of Simple Insulin Detemir Titration, Metformin Plus Liraglutide Compared to Simple Insulin Detemir Titration Plus Insulin Aspart and Metformin for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study: A 26 Week, Randomized, Open Label, Parallel-group, Intention to Treat Study

CompletedPH IVUniversity of Texas Southwestern Medical Centern=1572017

A Twenty-six Week, Randomized, Open-label, 2-arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Transition to Toujeo Compared to "Standard of Care" Insulin in Basal Insulin Treated Patients With Uncontrolled Type 2 Diabetes Mellitus, With Six-Month Extension

CompletedPH IVSanofin=6092017

A Twenty-six Week, Randomized, Open-label, 2-Arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Toujeo® Compared to "Standard of Care" Insulin for Initiating Basal Insulin in Insulin Naïve Patients With Uncontrolled Type 2 Diabetes Mellitus, With 6-Month Extension

CompletedPH IVSanofin=7052017

A 20-week, Randomised, Multi-centre, Open-labelled Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Titration Algorithms (3-0-3 Algorithm and 2-4-6-8 Algorithm) After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment in Korea

CompletedPH IVNovo Nordisk A/Sn=462015

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Study Investigating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes

CompletedPH INovo Nordisk A/Sn=1172026

A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes

CompletedPH INovo Nordisk A/Sn=302022

A Trial Comparing the Effect and Safety of Insulin Degludec Versus Insulin Detemir, Both in Combination With Insulin Aspart, in the Treatment of Pregnant Women With Type 1 Diabetes

CompletedPH IIINovo Nordisk A/Sn=2252020

CompletedPH IVKey trialSanofin=3,3042018

CompletedPH IVUniversity of Texas Southwestern Medical Centern=1572017

CompletedPH IVSanofin=6092017

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.

Diabetes, obesity & metabolism · 2009 · 131 cites